Try our Advanced Search for more refined results
Life Sciences
-
January 28, 2026
Crowell & Moring Adds Tech Firm IP Atty In Southern Calif.
Crowell & Moring LLP is expanding its California team, bringing in an intellectual property attorney most recently with biotechnology firm Grail as a partner in its Orange County office in Irvine.
-
January 28, 2026
ArentFox Schiff Launches Longevity Industry Group
ArentFox Schiff LLP on Wednesday announced the launch of a group geared toward advising companies focused on advancing wellness, preventive health care and the longevity of life.
-
January 28, 2026
LegitScript's Counterclaims Against PharmacyChecker Tossed
An Oregon federal court dismissed LegitScript's counterclaims accusing PharmacyChecker.com of making false statements about the legality of importing prescription drugs, in a suit accusing the pharmacy accreditation provider of blacklisting the price-checking website.
-
January 28, 2026
Robins Kaplan Takes Aim At Benicar MDL Fees Suit In NJ
Robins Kaplan LLP told a New Jersey federal court Wednesday that a suit over fees the firm collected in multidistrict litigation over blood pressure medication should be thrown out, saying it "parrot[s]" claims from earlier suits that were already dismissed.
-
January 28, 2026
Generics Makers Want Hospital Drug Data In Price-Fixing MDL
A group of 150 hospitals suing generic-drug makers for alleged price fixing in multidistrict litigation should hand over data on their drug purchases, the drugmakers have told a Pennsylvania federal court, arguing they don't sell directly to the hospitals and therefore have no records themselves.
-
January 28, 2026
3rd Circ. Appears Skeptical Of Quest's Early Win In 401(k) Suit
The Third Circuit on Wednesday pressed attorneys defending Quest Diagnostics Inc.'s pretrial defeat of a proposed class action from workers who alleged that their 401(k) savings were drained by underperforming investment funds, spotlighting the parties' disagreement over whether the lab company followed its own investment policy statement.
-
January 27, 2026
Ohio PBM Suit Belongs In Federal Court, 6th Circ. Rules
The Sixth Circuit on Tuesday ruled that Ohio's lawsuit accusing pharmacy benefit managers of driving up prescription prices through rebate schemes belongs in federal court, saying in an opinion recommended for publication that the suit imposes liability on conduct undertaken at the direction of a federal officer.
-
January 27, 2026
Lasik Provider Can't Shake Wiretap Claims In Tracking Row
The operator of a laser eye surgery website must face a proposed class action alleging it illegally shared patients' confidential medical information with Meta, a California federal judge ruled, finding that the plaintiff could continue to press allegations under state and federal wiretap law.
-
January 27, 2026
BioXcel Says Doctor Sent Fake Email About Alzheimer's Trial
Artificial intelligence-driven drugmaker BioXcel Therapeutics Inc. claimed a doctor in charge of a clinical trial site in Florida tried to cover up a failure to report an adverse event by submitting a fraudulent email to a federal inspector, according to a suit filed in Florida state court.
-
January 27, 2026
Kelley Drye Adds Ex-23andMe, Facebook Privacy Pros
Kelley Drye & Warren LLP said Monday it is boosting its privacy and information security practice with the addition of a former 23andMe attorney in California and a former Facebook attorney in Texas.
-
January 27, 2026
Medtronic Rival's VP Says Docs Praised Device But Didn't Buy
A vice president in charge of sales at Applied Medical testified Tuesday in a California federal trial over his company's antitrust claims against Medtronic, and said the overwhelmingly positive feedback Applied received from surgeons who used its advanced bipolar devices often didn't result in sales.
-
February 04, 2026
Law360 Seeks Members For Its 2026 Editorial Boards
Law360 is looking for avid readers of our publications to serve as members of our 2026 editorial advisory boards.
-
January 27, 2026
Biotech Fundraising A Good Sign For Public Markets
At the start of what many healthcare attorneys hope will be a busy year, public biotechs are raising cash, signaling a thawing public market and potentially fertile ground for IPOs.
-
January 27, 2026
CBP's Medical Care Oversight Needs Improvement, GAO Says
A report issued by the U.S. Government Accountability Office found that U.S. Customs and Border Protection sometimes failed to provide proper medical oversight for certain people in its custody, violating its own policies and guidance for medical care.
-
January 27, 2026
White House Pushed To Back PTAB Rule Change Proposal
Two groups representing inventors and startups have thrown their support behind the U.S. Patent and Trademark Office's proposal to limit America Invents Act patent reviews, saying it will give patent owners certainty and also protect against foreign challenges to domestic patents.
-
January 27, 2026
Investors Say Teva Can't Get Early Win In Price-Fixing Suit
Investors guided by Highfields Capital told a Connecticut federal court that Teva Pharmaceuticals can't escape their claims that its alleged collusion with other drugmakers to artificially inflate the price of generic drugs also inflated stock prices, reasoning that Teva executives falsely attributed the company's performance to factors other than the alleged price-fixing.
-
January 27, 2026
Mylan's Sanofi Insulin Suit Mostly Survives Dismissal Bid
A Pennsylvania federal judge Tuesday largely refused to dismiss Mylan Pharmaceuticals' antitrust lawsuit accusing Sanofi of unlawfully maintaining a monopoly in the market for injectable insulin glargine.
-
January 26, 2026
Generics Makers Fight Cert. In Cholesterol Drug Pricing MDL
Generic-drug makers sought to defeat a bid to certify proposed classes comprising thousands of pharmacies that indirectly purchased and resold generics at the center of sprawling price-fixing litigation, telling a Pennsylvania federal court Monday that certification would result in an "unmanageable trial."
-
January 26, 2026
Masimo Chafes Against Apple's Bid To Duck $634M IP Verdict
Masimo has urged a California federal court to turn down Apple's request for relief from its $634 million trial loss in the companies' patent infringement fight over the Apple Watch, arguing that the company has made "extraordinarily untimely" attempts to change the meaning of "patient monitor."
-
January 26, 2026
Ill. Judge Trims False Ad Suit Over Abbott Formula
An Illinois federal judge Friday dismissed several claims in a putative class action alleging Abbott Laboratories falsely advertised its toddler drinks sold under the Similac brand as nutritionally proper for children ages 12 months to 36 months, but largely allowed the parents' complaint to move forward.
-
January 26, 2026
Novo Nordisk Faces Class Claims Over GLP-1 Patent Tactics
A South Carolina drug company has launched a proposed class action against major pharmaceutical company Novo Nordisk, alleging it engaged in anticompetitive behavior to prolong its monopoly against generic competition for the GLP-1 drug Victoza.
-
January 26, 2026
O'Melveny Brings On Proskauer M&A Pro In California
O'Melveny & Myers LLP announced Monday that it added a corporate dealmaker to its Newport Beach, California, office from the Los Angeles office of Proskauer Rose LLP.
-
January 26, 2026
Zenas BioPharma Slams Investor's Revamped Fraud Claim
Zenas BioPharma has asked a Massachusetts federal judge to toss a putative investor class action targeting pre-initial public offering statements about the company's spending, saying it didn't hide that it had ramped up investment in research and development.
-
January 26, 2026
Catching Up With Delaware's Chancery Court
The Delaware Chancery Court wrapped up the week with a slate of high-stakes deal challenges, governance rulings and oversight decisions, including an emergency bid to block a $10.9 billion bank merger, a state Supreme Court reversal reshaping stockholder agreement litigation and a major opinion allowing sexual misconduct oversight claims to proceed.
-
January 23, 2026
DC Circ. Revives Terrorism Liability Suit Against Pharma Cos.
A D.C. Circuit panel revived a lawsuit Friday accusing pharmaceutical companies of aiding a Hezbollah-linked militia's terrorism in Iraq, saying the victims behind the case have adequately alleged that the companies' participation was conscious and voluntary.
Expert Analysis
-
Series
Fly-Fishing Makes Me A Better Lawyer
Much like skilled attorneys, the best anglers prize preparation, presentation and patience while respecting their adversaries — both human and trout, says Rob Braverman at Braverman Greenspun.
-
4 Ways GCs Can Manage Growing Service Of Process Volume
As automation and arbitration increase the volume of legal filings, in-house counsel must build scalable service of process systems that strengthen corporate governance and manage risk in real time, says Paul Mathews at Corporation Service Co.
-
Series
The Law Firm Merger Diaries: Forming Measurable Ties
Relationship-building should begin as early as possible in a law firm merger, as intentional pathways to bringing people together drive collaboration, positive client response, engagements and growth, says Amie Colby at Troutman.
-
AG Watch: Va. Insulin Price Probe Signals Rising Scrutiny
Virginia Attorney General Jason Miyares' recent investigation into insulin manufacturers and pharmacy benefit managers for allegedly colluding to artificially inflate insulin prices reflects a broader trend to leverage consumer protection authority in high-impact healthcare matters, and the upcoming leadership change is unlikely to diminish scrutiny in this area, says Chuck Slemp at Cozen O'Connor.
-
FDA's AI Deployment Brings New Potential And Risks
The U.S. Food and Drug Administration's recent announcement about making agentic artificial intelligence tools available to agency employees may portend accelerated regulatory timelines and lower costs for drug companies and consumers, but potential errors and biases will necessitate additional safeguards, says Angela Silva at Lewis Brisbois.
-
3 Key Takeaways From Planned Rescheduling Of Cannabis
An executive order reviving cannabis rescheduling represents a monumental change for the industry and, while the substance will remain illegal at the federal level, introduces several benefits, including improving state-legal cannabis operators' tax treatment, lowering the industry's legal risk profile, and leaving state-regulated markets largely intact, say attorneys at Dentons.
-
6 Issues That May Follow The 340B Rebate Pilot Challenge
Though the Health Resources and Services Administration withdrew a pending case to reconsider the controversial 340B rebate pilot program, a number of crucial considerations remain, including the likelihood of a rework and questions about what that rework might look like, say attorneys at Spencer Fane.
-
5 E-Discovery Predictions For 2026 And Beyond
2026 will likely be shaped by issues ranging from artificial intelligence regulatory turbulence to potential evidence rule changes, and e-discovery professionals will need to understand how to effectively guide the responsible and defensible adoption of emerging tools, while also ensuring effective safeguards, say attorneys at Littler.
-
Streamlining Product Liability MDLs With AI And Rule 16.1
With newly effective Rule 16.1 of the Federal Rules of Civil Procedure providing enhanced guidance on multidistrict litigation and the sophistication of artificial intelligence continuing to advance, parties have the opportunity to better confront the significant data challenges presented by product liability MDLs, say attorneys at Hollingsworth.
-
Business Considerations Amid Hemp Product Policy Change
With the passage of a bill fundamentally narrowing the federal definition of "hemp," there are practical and business considerations that brands, manufacturers and other parties should heed over the next year, including operational strategies, evaluating contract and counterparty risk, and tax implications, say attorneys at Foley Hoag.
-
Series
Judges On AI: How Courts Can Boost Access To Justice
Arizona Court of Appeals Judge Samuel A. Thumma writes that generative artificial intelligence tools offer a profound opportunity to enhance access to justice and engender public confidence in courts’ use of technology, and judges can seize this opportunity in five key ways.
-
Fed. Circ. In November: Looking For Patent 'Blaze Marks'
The Federal Circuit's recent decision in Duke v. Sandoz serves as a warning that when patentees craft claims, they must provide adequate "blaze marks" that direct a skilled artisan to the specific claimed invention, and not just the individual claimed elements in isolation, say attorneys at Knobbe Martens.
-
2025's Most Notable State AG Activity By The Numbers
State attorneys general were active in 2025, working across party lines to address federal regulatory gaps in artificial intelligence, take action on consumer protection issues, continue antitrust enforcement and announce large settlements on behalf of their citizens, say attorneys at Jenner & Block.
-
Opinion
The Case For Emulating, Not Dividing, The Ninth Circuit
Champions for improved judicial administration should reject the unfounded criticisms driving recent Senate proposals to divide the Ninth Circuit and instead seek to replicate the court's unique strengths and successes, says Ninth Circuit Judge J. Clifford Wallace.
-
How Rule 16.1 Streamlines And Validates Mass Tort Litigation
The new Rule 16.1 of the Federal Rules of Civil Procedure not only serves a practical purpose by endorsing early, structured case management and dispositive motion practice in multidistrict litigation, but also explicitly affirms the importance of MDL practice in the justice system, says Rocco Strangio at Milestone.